The University of Southampton
University of Southampton Institutional Repository

Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs

Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs
Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs
Background: [(123)I]N-omega-fluoropropyl-2beta-carbomethoxy-3beta-{4-iodophenyl}nortro pane ([(123)I]FP-CIT) single photon emission computed tomography (SPECT) is a frequently and routinely used technique to detect or exclude dopaminergic degeneration by imaging the dopamine transporter (DAT) in parkinsonian and demented patients. This technique is also used in scientific studies in humans, as well as in preclinical studies to assess the availability of DAT binding in the striatum. In routine clinical studies, but also in scientific studies, patients are frequently on medication and sometimes even use drugs of abuse. Moreover, in preclinical studies, animals will be anesthetized. Prescribed drugs, drugs of abuse, and anesthetics may influence the visual interpretation and/or quantification of [(123)I]FP-CIT SPECT scans.

Discussion: here, we discuss the basic principle of how drugs and anesthetics might influence the visual interpretation and/or quantification of [(123)I]FP-CIT SPECT scans. We also review drugs which are likely to have a significant influence on the visual interpretation and/or quantification of [(123)I]FP-CIT SPECT scans. Additionally, we discuss the evidence as to whether frequently prescribed drugs in parkinsonian and demented patients may have an influence on the visual interpretation and/or quantification of [(123)I]FP-CIT SPECT scans. Finally, we discuss our recommendations as to which drugs should be ideally withdrawn before performing a [(123)I]FP-CIT SPECT scan for routine clinical purposes. The decision to withdraw any medication must always be made by the specialist in charge of the patient's care and taking into account the pros and cons of doing so.
123I]FP-CIT SPECT, dopamine transporter, drugs, withdrawal, effects
1619-7070
424-438
Booij, Jan
9e068faf-7ba9-4155-a493-8d4ecdf1ee02
Kemp, Paul
f37a82f8-7613-439d-82dd-842d66ecfe58
Booij, Jan
9e068faf-7ba9-4155-a493-8d4ecdf1ee02
Kemp, Paul
f37a82f8-7613-439d-82dd-842d66ecfe58

Booij, Jan and Kemp, Paul (2008) Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. European Journal of Nuclear Medicine and Molecular Imaging, 35 (2), 424-438. (doi:10.1007/s00259-007-0621-0).

Record type: Article

Abstract

Background: [(123)I]N-omega-fluoropropyl-2beta-carbomethoxy-3beta-{4-iodophenyl}nortro pane ([(123)I]FP-CIT) single photon emission computed tomography (SPECT) is a frequently and routinely used technique to detect or exclude dopaminergic degeneration by imaging the dopamine transporter (DAT) in parkinsonian and demented patients. This technique is also used in scientific studies in humans, as well as in preclinical studies to assess the availability of DAT binding in the striatum. In routine clinical studies, but also in scientific studies, patients are frequently on medication and sometimes even use drugs of abuse. Moreover, in preclinical studies, animals will be anesthetized. Prescribed drugs, drugs of abuse, and anesthetics may influence the visual interpretation and/or quantification of [(123)I]FP-CIT SPECT scans.

Discussion: here, we discuss the basic principle of how drugs and anesthetics might influence the visual interpretation and/or quantification of [(123)I]FP-CIT SPECT scans. We also review drugs which are likely to have a significant influence on the visual interpretation and/or quantification of [(123)I]FP-CIT SPECT scans. Additionally, we discuss the evidence as to whether frequently prescribed drugs in parkinsonian and demented patients may have an influence on the visual interpretation and/or quantification of [(123)I]FP-CIT SPECT scans. Finally, we discuss our recommendations as to which drugs should be ideally withdrawn before performing a [(123)I]FP-CIT SPECT scan for routine clinical purposes. The decision to withdraw any medication must always be made by the specialist in charge of the patient's care and taking into account the pros and cons of doing so.

Full text not available from this repository.

More information

Published date: February 2008
Keywords: 123I]FP-CIT SPECT, dopamine transporter, drugs, withdrawal, effects

Identifiers

Local EPrints ID: 70096
URI: https://eprints.soton.ac.uk/id/eprint/70096
ISSN: 1619-7070
PURE UUID: bb568bb5-6c07-4920-bde5-a05b83ac39ba

Catalogue record

Date deposited: 21 Jan 2010
Last modified: 19 Jul 2019 23:46

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×